|
|
|
| Efficacy of Butylphthalide Combined with Edaravone Dexborneol in the Treatment of Patients with Large Cerebral Infarction and its Effect on Serum Related Indicators |
| CHEN Xiaoru, LIN Chong |
| Department of Neurology, Affiliated Hospital of Xi'an Medical College, Xi'an Shaanxi 710309 |
|
|
|
|
Abstract 【Objective】To investigate the efficacy of butylphthalide combined with edaravone dexborneol in the treatment of patients with large cerebral infarction (LCI) and its effect on serum neuron-specific enolase (NSE), astrocyte-derived protein (S100B), and glial fibrillary acidic protein (GFAP).【Methods】 A total of 120 patients with LCI were randomly divided into an observation group (treated with butylphthalide combined with edaravone dexborneol) and a control group (treated with edaravone dexborneol alone). The clinical efficacy, NIHSS scores and ADL scores before and after treatment were compared between the two groups. Serum levels of NSE, S100B, and GFAP, as well as whole blood viscosity and plasma viscosity before and after treatment, were measured and compared between the twomgroups. The incidence of adverse reactions in the two groups was also compared.【Results】 The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the NIHSS scores of both groups were significantly lower, and the ADL scores were significantly higher than before treatment (P<0.05). The NIHSS score in the observation group was lower than that in the control group, and the ADL score in the observation group was higher than that in the control group (P<0.05). Post-treatment serum levels of NSE, S100B, and GFAP, as well as whole blood viscosity and plasma viscosity, were significantly lower if compared to pre-treatment levels. And all these measurement levels in the observation group were lower than those in the control group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 The combination of butylphthalide and edaravone dexborneol is effective in treating LCI, improving neurological function, and reducing levels of NSE, S100B, and GFAP, as well as blood viscosity. This treatment enhances the quality of life and has good safety.
|
|
Received: 02 November 2023
|
|
|
|
|
|
[1] 陈卫,范蕾,于淼,等.大面积脑梗死患者中枢神经系统感染影响因素及NF-κB基因表达[J].中华医院感染学杂志,2023,33(3):359-363.
[2] 吴思缈,袁若圳,刘鸣.应当提倡大面积脑梗死后恶性脑水肿的预防理念及其研究[J].中华神经科杂志,2020,53(4):244-249.
[3] 刘前,邓倩,周静,等.依达拉奉右莰醇联合阿托伐他汀治疗老年急性脑梗死的临床疗效及对脑血流动力学的影响[J].中国老年学杂志,2023,43(2):276-279.
[4] 王晓宇,朱彩花,楼滟.血栓通联合丁苯酞对老年急性脑梗死血清中Fibulin-5、BDNF及S100B的影响[J].中华中医药学刊,2018,36(1):235-238.
[5] 翟羽佳.丁苯酞注射液联合依达拉奉治疗急性脑梗死的临床疗效和安全性研究[J].临床神经病学杂志,2018,31(5):380-381.
[6] 中华医学会神经病学分会神经重症协作组,中国医师协会神经内科医师分会神经重症专委会.大脑半球大面积梗死监护与治疗中国专家共识[J].中华医学杂志,2017,97(9):645-652.
[7] 中华医学会神经外科学分会,国家卫健委脑卒中筛查与防治工程委员会,海峡两岸医药卫生交流协会神经外科分会缺血性脑血管病学组.大面积脑梗死外科治疗指南[J].中华医学杂志,2021,101(45):3700-3711.
[8] 李法良,陈龙,李静宇.美国国立卫生研究院卒中量表评分和格拉斯哥昏迷评分对急性脑梗死患者溶栓治疗后出血的预测价值[J].中华老年医学杂志,2022,41(2):158-161.
[9] 刘文忠,王永和,符琼芳.芪归化痰消梗汤治疗对急性脑梗塞患者血液流变学、神经功能及ADL评分的影响[J].四川中医,2021,39(8):120-123.
[10] 陈国昌,石小峰,陆云涛.老年急性大面积脑梗死患者持续颅内压监测联合阶梯式治疗的效果分析[J].中风与神经疾病杂志,2020,37(8):707-709.
[11] 袁长红,吴晓宇,陈长春,等.急性脑梗死静脉溶栓后早期神经功能恶化的危险因素及预测模型分析[J].临床内科杂志,2021,38(6):396-398.
[12] 韩薇,徐宇浩,于明.依达拉奉右莰醇注射液治疗急性大动脉粥样硬化型脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(3):316-319.
[13] 陈冲,林秋,邱桂森.丁苯酞治疗脑梗死伴认知功能障碍的临床疗效观察[J].中西医结合心脑血管病杂志,2022,20(10):1879-1882.
[14] 王莉,郑佳丽,高蓉.茴拉西坦联合静脉溶栓对脑梗死患者神经功能及TNF-α、VEGF、GFAP、NSE的影响[J].广东医学,2019,40(7):1009-1011.
[15] 周莉,姚瑶,吴晓颖.血清NSE、S100B和D-D水平对急性脑梗死患者预后的评估价值[J].江苏医药,2021,47(10):1013-1016. |
|
|
|
2024, Vol. 41 
